Search

Your search keyword '"Buaboonnam,Jassada"' showing total 37 results
Start Over Author "Buaboonnam,Jassada" Publication Type Academic Journals
37 results on '"Buaboonnam,Jassada"'

1. Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group

Author

Monsereenusorn, Chalinee, Techavichit, Piti, Sathitsamitphong, Lalita, Lertvivatpong, Nawachai, Winaichatsak, Angkana, Chainansamit, Su-on, Buaboonnam, Jassada, Kuwatjanakul, Pitchayanan, Chotsampancharoen, Thirachit, Wangkittikal, Chonthida, Kanchanakamhaeng, Kittima, Suwannaying, Kunanya, Sripattanatadasakul, Pariwan, Wongruangsri, Siranee, Phalakornkul, Nattaporntira, Lertkovit, Oranooj, Sinlapamongkolkul, Phakatip, Songkhla, Pokpong Na, Prasertphol, Kerati, and Pakakasama, Samart

Published
2024
Full Text
View/download PDF

2. Retinoblastoma with and without Extraocular Tumor Extension: A Global Comparative Study of 3435 Patients

Author

Fabian, Ido Didi, Abdallah, Elhassan, Abdullahi, Shehu U., Abdulqader, Rula A., Abdulrahaman, Aminatu A., Abouelnaga, Sherif, Ademola-Popoola, Dupe S., Adio, Adedayo, Afifi, Mahmoud A., Afshar, Armin R., Aggarwal, Priyanka, Aghaji, Ada E., Ahmad, Alia, Akib, Marliyanti N.R., Akinsete, Adeseye M., Al Harby, Lamis, Al Mesfer, Saleh A., Al Ani, Mouroge H., Portabella, Silvia Alarcón, Al-Badri, Safaa A.F., Alcasabas, Ana Patricia A., Al-Dahmash, Saad A., Alejos, Amanda, Alemany-Rubio, Ernesto, Alfa Bio, Amadou I., Carreras, Yvania Alfonso, Al-Haddad, Christiane E., Al-Hussaini, Hamoud H.Y., Ali, Amany M., Alia, Donjeta B., Al-Jadiry, Mazin F., Al-Jumaly, Usama, Alkatan, Hind M., All-Eriksson, Charlotta, Al-Mafrachi, Ali A.R.M., Almeida, Argentino A., Alsawidi, Khalifa M., Al-Shaheen, Athar A.S.M., Al-Shammary, Entissar H., Amankwaa-Frempong, Doreen, Amiruddin, Primawita O., Armytasari, Inggar, Astbury, Nicholas J., Atalay, Hatice T., Ataseven, Eda, Atchaneeyasakul, La-ongsri, Atsiaya, Rose, Autrata, Rudolf, Balaguer, Julia, Balayeva, Ruhengiz, Barranco, Honorio, Bartoszek, Paulina, Bartuma, Katarina, Bascaran, Covadonga, Bechrakis, Nikolaos E., Popovic, Maja Beck, Begimkulova, Ainura S., Benmiloud, Sarra, Berete, Rokia C., Berry, Jesse L., Bhaduri, Anirban, Bhat, Sunil, Bhattacharyya, Arpita, Biewald, Eva M., Binkley, Elaine, Blum, Sharon, Bobrova, Nadia, Boldt, H. Culver, Bonanomi, Maria Teresa B.C., Bouda, Gabrielle C., Bouguila, Hédi, Brennan, Rachel C., Brichard, Bénédicte G., Buaboonnam, Jassada, Budiongo, Aléine, Burton, Matthew, Calderón-Sotelo, Patricia, Calle Jara, Doris A., Camuglia, Jayne E., Cano, Miriam R., Capra, Michael, Caspi, Shani, Cassoux, Nathalie, Castela, Guilherme, Castillo, Luis, Català-Mora, Jaume, Caviedes, Isabel, Chandramohan, Arthika, Chantada, Guillermo L., Chaudhry, Shabana, Chawla, Bhavna, Chen, Wensi, Chiwanga, Faraja S., Chuluunbat, Tsengelmaa, Cieslik, Krzysztof, Clark, Antony, Cockcroft, Ruellyn L., Comsa, Codruta, Correa Llano, Maria G., Corson, Timothy W., Couitchere, Line, Cowan-Lyn, Kristin E., Csóka, Monika, Dangboon, Wantanee, Das, Anirban, Das, Pranab, Das, Sima, Davanzo, Jacquelyn M., Davidson, Alan, De Francesco, Sonia, De Potter, Patrick, Delgado, Karina Q., Demirci, Hakan, Desjardins, Laurence, Diaz Coronado, Rosdali Y., Dimaras, Helen, Dodgshun, Andrew J., Donato Macedo, Carla R., Dragomir, Monica D., Du, Yi, Du Bruyn, Magritha, Du Plessis, Johannes P., Dudeja, Gagan, Eerme, Katrin, Eka Sutyawan, I Wayan, El Kettani, Asmaa, Elbahi, Amal M., Elder, James E., Elhaddad, Alaa M., Elhassan, Moawia M.A., Elzembely, Mahmoud M., Ericksen, Connor, Essuman, Vera A., Evina, Ted Grimbert A., Ezegwui, Ifeoma R., Fadoo, Zehra, Fandiño, Adriana C., Faranoush, Mohammad, Fasina, Oluyemi, Fernández, Delia D.P.G., Fernández-Teijeiro, Ana, Foster, Allen, Frenkel, Shahar, Fu, Ligia D., Fuentes-Alabi, Soad L., Garcia, Juan L., Aldana, David García, Garcia Pacheco, Henry N., Geel, Jennifer A., Ghassemi, Fariba, Girón, Ana V., Goenz, Marco A., Gold, Aaron S., Golberg, Hila, Gole, Glen A., Gomel, Nir, Gonzalez, Efren, Perez, Graciela Gonzalez, González-Rodríguez, Liudmira, Gorfine, Malka, Graells, Jaime, Gregersen, Pernille A., Grigorovski, Nathalia D.A.K., Guedenon, Koffi M., Gunasekera, D Sanjeeva, Gündüz, Ahmet K., Gupta, Himika, Gupta, Sanjiv, Gupta, Vineeta, Hadjistilianou, Theodora, Hamel, Patrick, Hamid, Syed A., Hamzah, Norhafizah, Hansen, Eric D., Harbour, J William, Hartnett, M. Elizabeth, Hasanreisoglu, Murat, Hassan, Sadiq, Hassan, Shadab, Hautz, Wojciech, Haydar, Huda A., Hederova, Stanislava, Hessissen, Laila, Lalaina, Hoby, Hongeng, Suradej, Hordofa, Diriba F., Hubbard, G. Baker, Hummlen, Marlies, Husakova, Kristina, Hussein Al-Janabi, Allawi N., Ibanga, Affiong A., Ida, Russo, Ilic, Vesna R., Islamov, Ziyavuddin, Jairaj, Vivekaraj, Janjua, Teyyeb A., Jeeva, Irfan, Ji, Xunda, Jo, Dong Hyun, Jones, Michael M., Amani Kabesha, Theophile B., Kabore, Rolande L., Kaliki, Swathi, Kalinaki, Abubakar, Kamsang, Pius, Kantar, Mehmet, Kapelushnik, Noa, Kardava, Tamar, Kebudi, Rejin, Keomisy, Jonny, Kepak, Tomas, Ketteler, Petra, Khan, Zohora J., Khaqan, Hussain A., Khetan, Vikas, Khodabande, Alireza, Khotenashvili, Zaza, Kim, Jonathan W., Kim, Jeong Hun, Kiratli, Hayyam, Kivelä, Tero T., Klett, Artur, Koç, Irem, Kosh Komba Palet, Jess Elio, Krivaitiene, Dalia, Kruger, Mariana, Kulvichit, Kittisak, Kuntorini, Mayasari W., Kyara, Alice, Lam, Geoffrey C., Larson, Scott A., Latinović, Slobodanka, Laurenti, Kelly D., Lavi, Yotam, Groznik, Alenka Lavric, Leverant, Amy A., Li, Cairui, Li, Kaijun, Limbu, Ben, Liu, Chun-Hsiu, Long, Quah Boon, López, Juan P., Lukamba, Robert M., Luna-Fineman, Sandra, Lutfi, Delfitri, Lysytsia, Lesia, Madgar, Shiran, Magrath, George N., Mahajan, Amita, Maitra, Puja, Maka, Erika, Makimbetov, Emil K., Maktabi, Azza M.Y., Maldonado, Carlos, Mallipatna, Ashwin, Manudhane, Rebecca, Manzhuova, Lyazat, Begue, Nieves Martín, Masud, Sidra, Matende, Ibrahim O., Mattosinho, Clarissa C.D.S., Matua, Marchelo, Mayet, Ismail, Mbumba, Freddy B., McKenzie, John D., Mehrvar, Azim, Mengesha, Aemero A., Menon, Vikas, Mercado, Gary John V.D.D., Mets, Marilyn B., Midena, Edoardo, Miller, Audra, Mishra, Divyansh K.C., Mndeme, Furahini G., Mohamedani, Ahmed A., Mohammad, Mona T., Moll, Annette C., Montero, Margarita M., Moreira, Claude, Mruthyunjaya, Prithvi, Msina, Mchikirwa S., Msukwa, Gerald, Mudaliar, Sangeeta S., Muhammad, Hassan, Muma, Kangwa I., Munier, Francis L., Murray, Timothy G., Musa, Kareem O., Mushtaq, Asma, Musika, Anne A., Mustak, Hamzah, Mustapha, Tajudeen, Muyen, Okwen M., Myezo, Khumo H., Naidu, Gita, Naidu, Natasha, Nair, Akshay Gopinathan, Natarajan, Sundaram, Naumenko, Larisa, Ndoye Roth, Paule Aïda, Nency, Yetty M., Neroev, Vladimir, Ng, Yvonne, Nikitovic, Marina, Nkanga, Elizabeth D., Nkumbe, Henry E., Numbi, Marcel N., Nummi, Kalle, Nuruddin, Murtuza, Nyaywa, Mutale, Nyirenda, Chinsisi, Obono-Obiang, Ghislaine, Oliver, Scott C.N., Ooporto, Joaquin, Ortega-Hernández, Miriam, Oscar, Alexander, Ossandon, Diego, Pagarra, Halimah, Paintsil, Vivian, Paiva, Luisa, Palanivelu, Mahesh Shanmugam, Papyan, Ruzanna, Parrozzani, Raffaele, Pascual Morales, Claudia R., Paton, Katherine E., Pe'er, Jacob, Calvo, Jesús Peralta, Perić, Sanja, Pham, Chau T.M., Philbert, Remezo, Plager, David A., Pochop, Pavel, Polania, Rodrigo A., Polyakov, Vladimir, Ponce, Jimena, Qadir, Ali O., Qayyum, Seema, Qian, Jiang, Rahman, Ardizal, Rajkarnikar, Purnima, Ramanjulu, Rajesh, Ramasubramanian, Aparna, Ramirez-Ortiz, Marco A., Randhawa, Jasmeen K., Raobela, Léa, Rashid, Riffat, Reddy, M. Ashwin, Renner, Lorna A., Reynders, David, Ribadu, Dahiru, Ritter-Sovinz, Petra, Rogowska, Anna, Rojanaporn, Duangnate, Romero, Livia, Roy, Soma R., Saab, Raya H., Saakyan, Svetlana, Sabhan, Ahmed H., Sagoo, Mandeep S., Said, Azza M.A., Saiju, Rohit, Salas, Beatriz, San Román Pacheco, Sonsoles, Sánchez, Gissela L., Sanchez Orozco, Alma Janeth, Sayalith, Phayvanh, Scanlan, Trish A., Schwab, Christoph, Sedaghat, Ahad, Seth, Rachna, Sgroi, Mariana, Shah, Ankoor S., Shakoor, Shawkat A., Sharma, Manoj K., Sherief, Sadik T., Shields, Carol L., Sia, David, Noorani Siddiqui, Sorath, Sidi cheikh, Sidi, Silva, Sónia, Singh, Arun D., Singh, Usha, Singha, Penny, Sitorus, Rita S., Skalet, Alison H., Soebagjo, Hendrian D., Sorochynska, Tetyana, Ssali, Grace, Stacey, Andrew W., Staffieri, Sandra E., Stahl, Erin D., Steinberg, David M., Stones, David K., Strahlendorf, Caron, Coleoni Suarez, Maria Estela, Sultana, Sadia, Sun, Xiantao, Superstein, Rosanne, Supriyadi, Eddy, Surukrattanaskul, Supawan, Suzuki, Shigenobu, Svojgr, Karel, Sylla, Fatoumata, Tamamyan, Gevorg, Tan, Deborah, Tandili, Alketa, Tang, Jing, Tarrillo Leiva, Fanny F., Tashvighi, Maryam, Tateshi, Bekim, Teh, Kok Hoi, Tehuteru, Edi S., Teixeira, Luiz F., Pompe, Manca Tekavcic, Thawaba, Abdullah Dahan M., Theophile, Tuyisabe, Toledano, Helen, Trang, Doan L., Traoré, Fousseyni, Tripathy, Devjyoti, Tuncer, Samuray, Tyau-Tyau, Harba, Umar, Ali B., Unal, Emel, Uner, Ogul E., Urbak, Steen F., Ushakova, Tatiana L., Usmanov, Rustam H., Valeina, Sandra, Valente, Paola, van Hoefen Wijsard, Milo, Vasquez Anchaya, Jacqueline Karina, Vaughan, Leon O., Veleva-Krasteva, Nevyana V., Verma, Nishant, Victor, Andi A., Viksnins, Maris, Villacís Chafla, Edwin G., Villegas, Victor M., Vishnevskia-Dai, Victoria, Waddell, Keith, Wali, Amina H., Wang, Yi-Zhuo, Wangtiraumnuay, Nutsuchar, Wetter, Julie A., Riono, Widiarti P., Wilson, Matthew W., Wime, Amelia D.C., Wiwatwongwana, Atchareeya, Wiwatwongwana, Damrong, Dod, Charlotte Wolley, Wong, Emily S., Wongwai, Phanthipha, Wu, Si-qi, Xiang, Daoman, Xiao, Yishuang, Xu, Bing, Xue, Kang, Yaghy, Antonio, Yam, Jason C., Yang, Huasheng, Yanga, Jenny M., Yaqub, Muhammad A., Yarovaya, Vera A., Yarovoy, Andrey A., Ye, Huijing, Yee, Roberto I., Yousef, Yacoub A., Yuliawati, Putu, López, Arturo M., Zein, Ekhtelbenina, Zhang, Yi, Zhilyaeva, Katsiaryna, Zia, Nida, Ziko, Othman A.O., Zondervan, Marcia, Schlüter, Sabrina, Bowman, Richard, and Vempuluru, Vijitha S.

Published
2025
Full Text
View/download PDF

3. Retinoblastoma in Asia: Clinical Presentation and Treatment Outcomes in 2112 Patients from 33 Countries

Author

Kaliki, Swathi, Vempuluru, Vijitha S., Mohamed, Ashik, Abdulqader, Rula Ahmed, Aggarwal, Priyanka, Ahmad, Alia, Akib, Marliyanti Nur Rahmah, Al Mesfer, Saleh A., Al Ani, Mouroge Hashim, Al-Badri, Safaa A.Faraj, Angeles Alcasabas, Ana Patricia, Al-Dahmash, Saad A., Al-Haddad, Christiane, Yahya Al-Hussaini, Hamoud Hodeish, Al-Jadiry, Mazin Faisal, Al-Jumaily, Usama, Alkatan, Hind Manaa, Razzaq Mahmood Al-Mafrachi, Ali Abdul, Samad Majeed Al-Shaheen, Athar Abdul, Al-Shammary, Entissar Hadi, Amiruddin, Primawita Oktarima, Armytasari, Inggar, Astbury, Nicholas John, Atalay, Hatice Tuba, Ataseven, Eda, Atchaneeyasakul, La-ongsri, Balayeva, Ruhengiz, Bascaran, Covadonga, Begimkulova, Ainura Suranovna, Bhaduri, Anirban, Bhat, Sunil, Bhattacharyya, Arpita, Blum, Sharon, Bowman, Richard, Buaboonnam, Jassada, Burton, Matthew J., Caspi, Shani, Chaudhry, Shabana, Chawla, Bhavna, Chen, Wensi, Chuluunbat, Tsengelmaa, Dangboon, Wantanee, Das, Anirban, Das, Pranab, Das, Sima, Du, Yi, Dudeja, Gagan, Eka Sutyawan, I Wayan, Fadoo, Zehra, Faranoush, Mohammad, Foster, Allen, Frenkel, Shahar, Ghassemi, Fariba, Gomel, Nir, Gunasekera, D Sanjeeva, Gündüz, Ahmet K., Gupta, Himika, Gupta, Sanjiv, Gupta, Vineeta, Hamid, Syed Ahmer, Hamzah, Norhafizah, Hasanreisoglu, Murat, Hassan, Shadab, Haydar, Huda Awni, Hongeng, Suradej, Hussein Al-Janabi, Allawi Noor, Islamov, Ziyavuddin, Janjua, Teyyeb Azeem, Jeeva, Irfan, Ji, Xunda, Jo, Dong Hyun, Kantar, Mehmet, Kapelushnik, Noa, Kebudi, Rejin, Keomisy, Jonny, Khan, Zohora Jameela, Khaqan, Hussain Ahmed, Khetan, Vikas, Khodabande, Alireza, Kim, Jeong Hun, Kiratli, Hayyam, Koç, Irem, Kulvichit, Kittisak, Kuntorini, Mayasari Wahyu, Li, Cairui, Li, Kaijun, Limbu, Ben, Liu, ChunHsiu, Lutfi, Delfitri, Mahajan, Amita, Maitra, Puja, Makimbetov, Emil Kojoshovich, Maktabi, Azza M.Y., Manzhuova, Lyazat, Masud, Sidra, Mehrvar, Azim, Menon, Vikas, John V Mercado, Gary, Chandra Mishra, Divyansh Kailash, Mohammad, Mona Tayseer, Mudaliar, Sangeeta Sanjay, Mushtaq, Asma, Nair, Akshay Gopinathan, Natarajan, Sundaram, Nency, Yetty Movieta, Neroev, Vladimir, Nuruddin, Murtuza, Pagarra, Halimah, Palanivelu, Mahesh Shanmugam, Papyan, Ruzanna, Pe'er, Jacob, Polyakov, Vladimir, Qadir, Ali Omer, Qayyum, Seema, Qian, Jiang, Quah, BoonLong, Rahman, Ardizal, Rajkarnikar, Purnima, Ramanjulu, Rajesh, Rashid, Riffat, Rojanaporn, Duangnate, Roy, Soma Rani, Saab, Raya Hamad, Saakyan, Svetlana, Sabhan, Ahmed Hatem, Saiju, Rohit, Sayalith, Phayvanh, Sedaghat, Ahad, Seth, Rachna, Shakoor, Shawkat Ara, Sharma, Manoj Kumar, Siddiqui, Sorath Noorani, Singh, Usha, Singha, Penny, Sitorus, Rita S., Soebagjo, Hendrian D., Sultana, Sadia, Sun, Xiantao, Supriyadi, Eddy, Surukrattanaskul, Supawan, Suzuki, Shigenobu, Tan, Deborah, Tang, Jing, Tashvighi, Maryam, Teh, Kok Hoi, Tehuteru, Edi Setiawan, Thawaba, Abdullah Dahan M., Toledano, Helen, Le Trang, Doan, Tripathy, Devjyoti, Tuncer, Samuray, Unal, Emel, Ushakova, Tatiana L., Usmanov, Rustam, Verma, Nishant, Victor, Andi Arus, Vishnevskia-Dai, Victoria, Wang, Yi-Zhuo, Wangtiraumnuay, Nutsuchar, Riono, Widiarti Pandu, Wiwatwongwana, Atchareeya, Wiwatwongwana, Damrong, Wong, Emily S., Wongwai, Phanthipha, Wu, Si-qi, Xiang, Daoman, Xiao, Yishuang, Xu, Bing, Xue, Kang, Yam, Jason C., Yang, Huasheng, Yaqub, Muhammad Amer, Yarovaya, Vera A., Yarovoy, Andrey A., Ye, Huijing, Yousef, Yacoub Abdallah, Yuliawati, Putu, Zhang, Yi, Zia, Nida, Zondervan, Marcia, Fabian, Ido Didi, and Sthapit, Purnima Rajkarnikar

Published
2024
Full Text
View/download PDF

4. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

Author

Buaboonnam, Jassada, Ekwattanakit, Supachai, Khunhapinant, Archrob, Loka, Efthalia, Moraki, Maria, Flevari, Pagona, Dimopoulou, Maria, Bartzi, Vasiliki, Daadaa, Hisham, El Hasbani, Georges, Koussa, Suzanne, Tartaglione, Immacolata, Ammendola, Federica, Scianguetta, Saverio, Puglia, Marta, Ferrara, Ilaria, Ferrero, Giovanni, Gaglioti, Carmen, Longo, Filomena, Turrini, Silvia, Voi, Vincenzo, Cassinerio, Elena, De, Anna, Graziadei, Giovanna, Marcon, Alessia, Migone De Amicis, Margherita, Motta, Irene, Cinque, Patrizia, Pannone, Bruno, Ricchi, Paolo, Balocco, Manuela, Carrara, Paola, Della Rovere, Francesco, Lamagna, Martina, Pinto, Valeria, Quintino, Sabrina, Eleftheriou, Perla, Garbowski, Maciej, de Kreuk, Arne, Carson, Susan, Denton, Christopher, Hofstra, Tom, Veluswamy, Sayany, Wood, John, Badawy, Sherif, Bercovitz, Rachel, Bhat, Rukhmi, Calamaras, Diane, Liem, Robert, Mack, Astrid, Taher, Ali T, Cappellini, Maria Domenica, Kattamis, Antonis, Voskaridou, Ersi, Perrotta, Silverio, Piga, Antonio G, Filosa, Aldo, Porter, John B, Coates, Thomas D, Forni, Gian Luca, Thompson, Alexis A, Musallam, Khaled M, Backstrom, Jay T, Esposito, Oriana, Giuseppi, Ana Carolina, Kuo, Wen-Ling, Miteva, Dimana, Lord-Bessen, Jennifer, Yucel, Aylin, Zinger, Tatiana, Shetty, Jeevan K, and Viprakasit, Vip

Published
2022
Full Text
View/download PDF

5. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries

Author

Fabian, Ido Didi, Abdallah, Elhassan, Abdullahi, Shehu U, Abdulqader, Rula A, Abdulrahaman, Aminatu A, Abouelnaga, Sherif, Ademola-Popoola, Dupe S, Adio, Adedayo, Afifi, Mahmoud A, Afshar, Armin R, Aggarwal, Priyanka, Aghaji, Ada E, Ahmad, Alia, Akib, Marliyanti NR, Akinsete, Adeseye, Al Harby, Lamis, Al Mesfer, Saleh, Al Ani, Mouroge H, Alarcón Portabella, Silvia, Al-Badri, Safaa AF, Alcasabas, Ana Patricia A, Al-Dahmash, Saad A, Alejos, Amanda, Alemany-Rubio, Ernesto, Alfa Bio, Amadou I, Alfonso Carreras, Yvania, Al-Haddad, Christiane E, Al-Hussaini, Hamoud HY, Ali, Amany M, Alia, Donjeta B, Al-Jadiry, Mazin F, Al-Jumaily, Usama, Alkatan, Hind M, All-Eriksson, Charlotta, Al-Mafrachi, Ali ARM, Almeida, Argentino A, Alsawidi, Khalifa M, Al-Shaheen, Athar ASM, Al-Shammary, Entissar H, Amankwaa-Frempong, Doreen, Amiruddin, Primawita O, Armytasari, Inggar, Astbury, Nicholas J, Atalay, Hatice T, Ataseven, Eda, Atchaneeyasakul, La-ongsri, Atsiaya, Rose, Autrata, Rudolf, Balaguer, Julia, Balayeva, Ruhengiz, Barranco, Honorio, Bartoszek, Paulina, Bartuma, Katarina, Bascaran, Covadonga, Bechrakis, Nikolaos E, Beck Popovic, Maja, Begimkulova, Ainura S, Benmiloud, Sarra, Berete, Rokia C, Berry, Jesse L, Bhaduri, Anirban, Bhat, Sunil, Bhattacharyya, Arpita, Biewald, Eva M, Binkley, Elaine, Blum, Sharon, Bobrova, Nadia, Boldt, H.C., Bonanomi, Maria Teresa BC, Bouda, Gabrielle C, Bouguila, Hédi, Brennan, Rachel C, Brichard, Bénédicte G, Buaboonnam, Jassada, Budiongo, Aléine, Burton, Matthew J, Calderón-Sotelo, Patricia, Calle Jara, Doris A, Camuglia, Jayne E, Cano, Miriam R, Capra, Michael, Caspi, Shani, Cassoux, Nathalie, Castela, Guilherme, Castillo, Luis, Català-Mora, Jaume, Cavieres, Isabel, Chandramohan, Arthika, Chantada, Guillermo L, Chaudhry, Shabana, Chawla, Bhavna, Chen, Wensi, Chiwanga, Faraja S, Chuluunbat, Tsengelmaa, Cieslik, Krzysztof, Clark, Antony, Cockcroft, Ruellyn L, Comsa, Codruta, Correa Llano, Maria G, Corson, Timothy W, Couitchere, Line, Cowan-Lyn, Kristin E, Csóka, Monika, Dangboon, Wantanee, Das, Anirban, Das, Pranab, Das, Sima, Davanzo, Jacquelyn M, Davidson, Alan, De Francesco, Sonia, De Potter, Patrick, Quintero D, Karina, Demirci, Hakan, Desjardins, Laurence, Díaz Coronado, Rosdali Y, Dimaras, Helen, Dodgshun, Andrew J, Donato Macedo, Carla R, Dragomir, Monica D, Du, Yi, Du Bruyn, Magritha, Du Plessis, Johannes, Dudeja, Gagan, Eerme, Katrin, Eka Sutyawan, I Wayan, El Kettani, Asmaa, Elbahi, Amal M, Elder, James E, Elhaddad, Alaa M, Elhassan, Moawia MA, Elzembely, Mahmoud M, Ericksen, Connor, Essuman, Vera A, Evina, Ted Grimbert A, Ezegwui, Ifeoma R, Fadoo, Zehra, Fandiño, Adriana C, Faranoush, Mohammad, Fasina, Oluyemi, Fernández, Delia DPG, Fernández-Teijeiro, Ana, Foster, Allen, Frenkel, Shahar, Fu, Ligia D, Fuentes-Alabi, Soad L, Garcia, Juan L, García Aldana, David, Garcia Pacheco, Henry N, Geel, Jennifer A, Ghassemi, Fariba, Girón, Ana V, Goenz, Marco A, Gold, Aaron S, Goldberg, Hila, Gole, Glen A, Gomel, Nir, Gonzalez, Efren, Gonzalez Perez, Graciela, González-Rodríguez, Liudmira, Gorfine, Malka, Graells, Jaime, Gregersen, Pernille A, Grigorovski, Nathalia DAK, Guedenon, Koffi M, Gunasekera, D Sanjeeva, Gündüz, Ahmet K, Gupta, Himika, Gupta, Sanjiv, Gupta, Vineeta, Hadjistilianou, Theodora, Hamel, Patrick, Hamid, Syed A, Hamzah, Norhafizah, Hansen, Eric D, Harbour, J William, Hartnett, M. Elizabeth, Hasanreisoglu, Murat, Muhammad, Hassan, Hassan, Sadiq, Hassan, Shadab, Hautz, Wojciech, Haydar, Huda, Hederova, Stanislava, Hessissen, Laila, Hongeng, Suradej, Hordofa, Diriba F, Hubbard, G. Baker, Hummelen, Marlies, Husakova, Kristina, Hussein Al-Janabi, Allawi N, Ibanga, Affiong, Ida, Russo, Ilic, Vesna R, Islamov, Ziyavuddin, Jairaj, Vivekaraj, Janjua, Teyyeb, Jeeva, Irfan, Ji, Xunda, Jo, Dong Hyun, Jones, Michael M, Kabesha Amani, Theophile B, Kabore, Rolande L, Kaliki, Swathi, Kalinaki, Abubakar, Kamsang, Pius, Kantar, Mehmet, Kapelushnik, Noa, Kardava, Tamar, Kebudi, Rejin, Keomisy, Jonny, Kepak, Tomas, Ketteler, Petra, Khan, Zohora J, Khaqan, Hussain A, Khetan, Vikas, Khodabande, Alireza, Khotenashvili, Zaza, Kim, Jonathan W, Kim, Jeong Hun, Kiratli, Hayyam, Kivela, Tero T., Klett, Artur, Koç, Irem, Kosh Komba Palet, Jess Elio, Krivaitiene, Dalia, Kruger, Mariana, Kulvichit, Kittisak, Kuntorini, Mayasari W, Kyara, Alice, Lam, Geoffrey C, Larson, Scott A, Latinović, Slobodanka, Laurenti, Kelly D, Lavy, Yotam, Lavric Groznik, Alenka, Leverant, Amy A, Li, Cairui, Li, Kaijun, Limbu, Ben, Liu, Chun-Hsiu, Quah, BoonLong, López, Juan P, Lukamba, Robert M, Luna-Fineman, Sandra, Lutfi, Delfitri, Lysytsia, Lesia, Madgar, Shiran, Magrath, George N, Mahajan, Amita, Maitra, Puja, Maka, Erika, Makimbetov, Emil K, Maktabi, Azza, Maldonado, Carlos, Mallipatna, Ashwin, Manudhane, Rebecca, Manzhuova, Lyazat, Martín-Begue, Nieves, Masud, Sidra, Matende, Ibrahim O, Mattosinho, Clarissa CDS, Matua, Marchelo, Mayet, Ismail, Mbumba, Freddy B, McKenzie, John D, Mehrvar, Azim, Mengesha, Aemero A, Menon, Vikas, Mercado, Gary John V, Mets, Marilyn B, Midena, Edoardo, Miller, Audra, Mishra, Divyansh KC, Mndeme, Furahini G, Mohamedani, Ahmed A, Mohammad, Mona T, Moll, Annette C, Montero, Margarita M, Moreira, Claude, Mruthyunjaya, Prithvi, Msina, Mchikirwa S, Msukwa, Gerald, Mudaliar, Sangeeta S, Muma, Kangwa I M, Munier, Francis L, Murray, Timothy G, Musa, Kareem O, Mushtaq, Asma, Musika, Anne A, Mustak, Hamzah, Mustapha, Tajudeen, Muyen, Okwen M, Myezo, Khumo H, Naidu, Gita, Naidu, Natasha, Nair, Akshay Gopinathan, Natarajan, Sundaram, Naumenko, Larisa, Ndoye Roth, Paule Aïda, Nency, Yetty M, Neroev, Vladimir, Ng, Yvonne, Nikitovic, Marina, Nkanga, Elizabeth D, Nkumbe, Henry E, Numbi, Marcel N, Nummi, Kalle, Nuruddin, Murtuza, Nyaywa, Mutale, Nyirenda, Chinsisi, Obono-Obiang, Ghislaine, Oliver, Scott CN, Oporto, Joaquin, Ortega-Hernández, Miriam, Oscar, Alexander H, Ossandon, Diego, Pagarra, Halimah, Paintsil, Vivian, Paiva, Luisa, Palanivelu, Mahesh Shanmugam, Papyan, Ruzanna, Parrozzani, Raffaele, Pascual Morales, Claudia R, Paton, Katherine E, Pe'er, Jacob, Peralta Calvo, Jesús, Perić, Sanja, Pham, Chau TM, Philbert, Remezo, Plager, David A, Pochop, Pavel, Polania, Rodrigo A., Polyakov, Vladimir, Ponce, Jimena, Qadir, Ali O, Qayyum, Seema, Qian, Jiang, Refaeli, David, Rahman, Ardizal, Rajkarnikar, Purnima, Ramanjulu, Rajesh, Ramasubramanian, Aparna, Ramirez-Ortiz, Marco A, Randhawa, Jasmeen K, Randrianarisoa, Hoby Lalaina, Raobela, Léa, Rashid, Riffat, Reddy, M.A., Renner, Lorna A, Reynders, David, Ribadu, Dahiru, Ritter-Sovinz, Petra, Rogowska, Anna, Rojanaporn, Duangnate, Romero, Livia, Roy, Soma R, Saab, Raya H, Saakyan, Svetlana, Sabhan, Ahmed H, Sagoo, Mandeep S, Said, Azza MA, Saiju, Rohit, Salas, Beatriz, San Román Pacheco, Sonsoles, Sánchez, Gissela L, Sanchez Orozco, Alma Janeth, Sayalith, Phayvanh, Scanlan, Trish A, Schlüter, Sabrina, Schwab, Christoph, Sedaghat, Ahad, Seth, Rachna, Sgroi, Mariana, Shah, Ankoor S, Shakoor, Shawkat A, Sharma, Manoj K, Sherief, Sadik T, Shields, Carol L, Sia, David, Siddiqui, Sorath Noorani, Sidi cheikh, Sidi, Silva, Sónia, Singh, Arun D, Singh, Usha, Singha, Penny, Sitorus, Rita S, Skalet, Alison H, Soebagjo, Hendrian D, Sorochynska, Tetyana, Ssali, Grace, Stacey, Andrew W, Staffieri, Sandra E, Stahl, Erin D, Steinberg, David M, Stones, David K, Strahlendorf, Caron, Suarez, Maria Estela Coleoni, Sultana, Sadia, Sun, Xiantao, Superstein, Rosanne, Supriyadi, Eddy, Surukrattanaskul, Supawan, Suzuki, Shigenobu, Svojgr, Karel, Sylla, Fatoumata, Tamamyan, Gevorg, Tan, Deborah, Tandili, Alketa, Tang, Jing, Tarrillo Leiva, Fanny F, Tashvighi, Maryam, Tateshi, Bekim, Teh, Kok Hoi, Tehuteru, Edi S, Teixeira, Luiz F, Tekavcic Pompe, Manca, Thawaba, Abdullah Dahan M, Theophile, Tuyisabe, Toledano, Helen, Trang, Doan L, Traoré, Fousseyni, Tripathy, Devjyoti, Tuncer, Samuray, Tyau-Tyau, Harba, Umar, Ali B, Unal, Emel, Uner, Ogul E, Urbak, Steen F, Ushakova, Tatiana L, Usmanov, Rustam H, Valeina, Sandra, Valente, Paola, van Hoefen Wijsard, Milo, Vasquez Anchaya, Jacqueline Karina, Vaughan, Leon O, Veleva-Krasteva, Nevyana V, Verma, Nishant, Victor, Andi A, Viksnins, Maris, Villacís Chafla, Edwin G, Villegas, Victor M, Vishnevskia-Dai, Victoria, Waddell, Keith, Wali, Amina H, Wang, Yi-Zhuo, Wangtiraumnuay, Nutsuchar, Wetter, Julie, Widiarti, Widiarti, Wilson, Matthew W, Wime, Amelia DC, Wiwatwongwana, Atchareeya, Wiwatwongwana, Damrong, Wolley Dod, Charlotte, Wong, Emily S, Wongwai, Phanthipha, Wu, Si-qi, Xiang, Daoman, Xiao, Yishuang, Xu, Bing, Xue, Kang, Yaghy, Antonio, Yam, Jason C, Yang, Huasheng, Yanga, Jenny M, Yaqub, Muhammad A, Yarovaya, Vera A, Yarovoy, Andrey A, Ye, Huijing, Yee, Roberto I, Yousef, Yacoub A, Yuliawati, Putu, Zapata López, Arturo M, Zein, Ekhtelbenina, Zhang, Yi, Zhilyaeva, Katsiaryna, Zia, Nida, Ziko, Othman AO, Zondervan, Marcia, and Bowman, Richard

Published
2022
Full Text
View/download PDF

10. Metastatic Death Following Ophthalmic Artery Chemotherapy for Retinoblastoma: A Systematic Review and Meta-analysis.

Author

Leelakanok, Nattawut, Atchaneeyasaku, La-ongsri, Songsaeng, Dittapong, Methaneethorn, Janthima, Sanpakit, Kleebsabai, and Buaboonnam, Jassada

Subjects
RETINOBLASTOMA, CANCER chemotherapy, CANCER treatment, MEDLINE, PHYSICIANS' attitudes
Abstract

Objective: The use of ophthalmic artery chemotherapy (OAC) as a front-line and salvage therapy for retinoblastoma has grown. However, the risk of metastatic death in these patients remains unclear. Materials and Methods: This study of metastatic deaths in OAC may benefit physicians managing retinoblastoma patients. A literature search of Medline, Scopus, Science Direct, and CINAHL was conducted from conception until November 2023. The primary outcome was metastatic death in patients treated with OAC. Results: From the 219 evaluated articles, nine met the inclusion criteria. A total of 596 (635 eyes) patients were treated with OAC; and 20 cases resulted in death due to metastasis of the retinoblastoma. The metastatic mortality rate was 2.5% (95% confidence interval: 0.8%-4.2%) which was statistically significant (p < 0.05). The central nervous system was the most common site of metastasis, followed by multiple sites of metastasis. Conclusion: OAC treatment is associated with the risk of metastatic death, but it is lower than the overall mortality rate of retinoblastoma. Further studies to identify the risk of metastasis are needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Outcomes of Overt and Non-overt Disseminated Intravascular Coagulation Using the ISTH DIC Scoring System in Children: A Single-Center Study.

Author

Buaboonnam, Jassada, Wangkittikal, Chonthida, Narkbunnam, Nattee, Vathana, Nassawee, Takpradit, Chayamon, Phuakpet, Kamon, Sinlapamongkolkul, Phakatip, Sanpakit, Kleebsabai, Karaketklang, Khemajira, and Pongtanakul, Bunchoo

Subjects
*DISSEMINATED intravascular coagulation, *FIBRIN fibrinogen degradation products, *ADULT respiratory distress syndrome, *PLATELET count, *DEATH rate
Abstract

Background: Several disseminated intravascular coagulation (DIC) scoring systems are used for prognosticating the clinical outcomes of patients with DIC. However, research on children is scarce. Therefore, this study compared the clinical outcomes of overt and non-overt DIC using the International Society on Thrombosis and Hemostasis (ISTH) DIC scoring system. Methods: This retrospective study reviewed data on children aged one month to 15 years diagnosed with DIC between 2003 and 2014. Results: Of 244 patients, 179 (73.4%) had overt DIC, and 65 (26.6%) had non-overt DIC. The most common causes were infection (84.8%), tissue injury (7%), and malignancies (2.9%). The 28-day case fatality rate was significantly higher for overt than non-overt DIC (76% vs. 15.6%; P < 0.001). DIC scores were significantly associated with mortality (R² = 0.89). Each clinical parameter (platelet count, prothrombin time, and fibrin degradation products) was associated with mortality (P = 0.01). On multivariable analysis, the factors associated with death were platelet counts = 50 000 cells/mm³ (OR, 2.42; 95% CI, 1.08-5.42; P = 0.031); overt DIC score (OR, 7.62; 95% CI, 2.94-19.75; P < 0.001); renal dysfunction (OR, 2.92; 95% CI, 1.34-6.37; P = 0.007); shock (OR, 39.62; 95% CI, 4.99-314.84; P = 0.001); and acute respiratory distress syndrome (OR, 25.90; 95% CI, 3.12-214.80; P = 0.003). Conclusions: The 28-day case-fatality rate was significantly higher for patients with overt than non-overt DIC and concordant with ISTH scores. ISTH DIC scores can be used as a clinical predictor for DIC in children. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. ITPA Polymorphisms and the Incidence of Toxicities in Children with Acute Lymphoblastic Leukemia.

Author

Svasdisant, Patpetra, Glomglao, Waraporn, Siraprapapat, Preeyanun, Inthararujikul, Wiyakan, Tachavanich, Kalaya, Boonthimat, Chetsada, Ardsiri, Sakkarin, Kochpinchon Chansing, Sriprach, Suwimon, Tongsai, Sasima, Sinlapamongkolkul, Phakatip, Sanpakit, Kleebsabai, and Buaboonnam, Jassada

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, GENE frequency, INORGANIC pyrophosphatase
Abstract

Background: 6-Mercaptopurine (6-MP), a thiopurine agent, is a essential medication for treating pediatric acute lymphoblastic leukemia (ALL). However, its side effects of neutropenia and hepatotoxicity might interrupt treatment, resulting in poor outcomes. Inosine triphosphate pyrophosphatase (ITPA), an enzyme in the thiopurine pathway, may prevent the accumulation of toxic thiopurine metabolites. Studies on ITPA and thiopurine-associated toxicities are scarce. Methods: This study retrospectively investigated 1- to 15-year-old children with ALL who received 6-MP during the maintenance phase of treatment between 2000 and 2020. Toxicity during the first year of maintenance therapy and the mean dose of 6-MP were analyzed. Results: The 209 patients had a median age of 4.8 (0.3-14.8) years. Of these, 124 patients (59.3%) had wild-type ITPA, 73 patients (34.9%) had heterozygous ITPA 94C>A (hetITPA), and 12 patients (5.7%) had homozygous ITPA 94C>A (homITPA), with an allele frequency of 0.23. The incidence of neutropenia among ITPA polymorphisms did not significantly differ (P = 0.813). In patients harboring homITPA, transaminitis was more frequent than other polymorphisms but without a significant difference (P = 0.063). The mean dose of 6-MP for patients with homITPA was significantly lower than that for patients with hetITPA or wild-type ITPA (P = 0.016). Conclusions: HomITPA had a higher incidence of transaminitis and required a significantly larger dose reduction of 6-MP than wild-type ITPA. Further study is warranted to elucidate the effects of ITPA polymorphisms on toxicity in patients with ALL treated with 6-MP. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Hemoglobin H Disease and Growth: A Comparative Study of DHbH and NDHbH Patients.

Author

Hunnuan, Issanun, Sanpkit, Kleebsabai, Lertbannaphong, Ornsuda, and Buaboonnam, Jassada

Subjects
GLOBIN genes, HEMOGLOBINS, PEDIATRIC endocrinology, STANDARD deviations, HOSPITAL patients
Abstract

Background: Hemoglobin H disease (HbH), a hemoglobinopathy resulting from abnormal alpha globin genes, is classified into two categories: deletional HbH (DHbH) and nondeletional HbH (NDHbH). The alpha-mutation genotypes exhibit a range of clinical anemias, which differentially impact patient growth. Objectives: This retrospective study assessed the growth of HbH patients at Siriraj Hospital, Mahidol University. Methods: Patients diagnosed with HbH between January 2005 and April 2021 were analyzed using growth standard scores of the Thai Society for Pediatric Endocrinology (2022 version) and BMIfor- age Z scores of the World Health Organization. Growth failure was defined as a patient's height for age exceeding two standard deviations below the mean. Results: Of the 145 HbH patients, 75 (51.7%) had NDHbH, with --SEA/αCSα being the most common genotype (70 patients; 93.3%). The mean baseline hemoglobin level was significantly lower in NDHbH patients than in DHbH patients (8.16 ± 0.93 g/dL vs. 9.51 ± 0.68 g/dL; P < 0.001). Splenomegaly and growth failure prevalences were higher in NDHbH patients (37.3% vs. 0%, with P < 0.001, and 22.7% vs. 8.6%, with P = 0.020, respectively). Multivariable analysis revealed splenomegaly > 3 cm was associated with growth failure (OR = 4.28; 95% CI, 1.19-15.39; P = 0.026). Conclusions: NDHbH patients exhibited lower hemoglobin levels and more pronounced splenomegaly than DHbH patients. Growth failure can occur in both HbH types but appears more prevalent in NDHbH. Close monitoring of growth velocity is essential, and early treatment interventions may be required to prevent growth failure. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Clinical Outcomes of Extracranial Germ Cell Tumors: A Single Institute's Experience.

Author

Laohverapanich, Kamala, Buaboonnam, Jassada, Vathana, Nassawee, Sanpakit, Kleebsabai, Takpradit, Chayamon, Narkbunnum, Nattee, Pongtanakul, Bunchoo, Sowithayasakul, Panjarat, and Phuakpet, Kamon

Subjects
GERM cell tumors, CHILDHOOD cancer, COMBINATION drug therapy, CANCER statistics, LEUKEMIA in children
Abstract

Objective: To determine the clinical features and treatment outcomes of pediatric extracranial germ cell tumor (EGCT) in Thailand. Materials and Methods: A retrospective chart review of children under 15 years old with newly diagnosed EGCT who were treated at Faculty of Medicine Siriraj Hospital from January, 2004 to December, 2013 was conducted. Results: Forty-four patients were included in the study. The median age at diagnosis was 1.74 years (1 day-14.7 years) with the median follow up time of 6.9 years (14 days-15.2 years). Twenty-eight patients (64%) had extragonadal tumor. The most common primary tumor location was the sacrococcygeal area. Majority of the patients (61%) had malignant EGCT; yolk sac tumor was the most common diagnosis. Six patients (14%) had stage IV disease. Forty patients (91%) underwent surgery; 27 patients (61%) received chemotherapy. Thirty-eight patients (86%) achieved remission; 3 patients (7%) subsequently relapsed at a median time of 1 year. Eight patients (18%) died, mostly from tumor progression. The 5-year event-free survival (EFS) and overall survival (OS) rate were 78.3% and 81.1%, respectively. Patients achieving total tumor removal had significantly better 5-year EFS and OS. Cox regression analysis revealed that the adequacy of surgery was the only prognostic factor for survival. Conclusion: The survival rate of pediatric EGCT in our study was relatively favorable, but still inferior to that of developed countries. Novel therapy may be warranted for those patients who are unresponsive to the current treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience.

Author

Takpradit, Chayamon, Wangkittikal, Chonthida, Rungmaitree, Supattra, Buaboonnam, Jassada, Narkbunnam, Nattee, Phuakpet, Kamon, Vathana, Nassawee, Sanpakit, Kleebsabai, and Pongtanakul, Bunchoo

Subjects
HEMATOPOIETIC stem cell transplantation, FEBRILE neutropenia, MYCOSES, FLUCONAZOLE
Abstract

Background: Invasive fungal diseases (IFDs) are common and contribute to mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). The relative efficacies of posaconazole (POS) and fluconazole (FLU) as primary antifungal prophylaxes are uncertain. Methods: A retrospective study was performed on children treated with allogeneic HSCT who received POS or FLU during the early neutropenic period. The efficacies, safety, and tolerabilities of the prophylaxes were compared. Results: Data on 78 HSCT recipients were analyzed. Most had thalassemia (58%). Pre-engraftment, POS and FLU were administered to 41 and 37 cases, respectively. There were no proven cases of IFD. However, 2 POS cases and 1 FLU case had probable IFDs. The IFD incidences of the POS (5%) and FLU (3%) groups demonstrated no statistical difference (p = 0.620). Of the 75 surviving cases receiving FLU post-engraftment (including 39 cases previously given POS), 3 had proven IFDs whereas 3 had probable IFDs (total, 6 [8%]) within 1 year post-HSCT. No cases discontinued the prophylaxes due to drug intolerance. The common adverse events with POS and FLU were not significantly different. Only 19% of the patients achieved the therapeutic POS level, with a starting dose of 4 mg/kg thrice daily. Conclusion: POS and FLU demonstrate comparable levels of effectiveness, safety, and tolerability as IFD prophylaxes for neutropenic children treated with allogeneic HSCT. Determination of the optimum POS dose and duration requires larger studies. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

22. Clinical outcomes and prognosis of Thai retinoblastoma patients.

Author

Prajantawanich, Kaewpanpat, Sanpakit, Kleebsabai, Narkbunnam, Nattee, Vathana, Nassawee, Takpradit, Chayamon, Phuakpet, Kamon, Pongtanakul, Bunchoo, Atchaneeyasakul, La‐ongsri, Sinlapamongkolkul, Phakatip, and Buaboonnam, Jassada

Subjects
ACQUISITION of data methodology, CONFIDENCE intervals, GLAUCOMA, RETROSPECTIVE studies, CANCER patients, TREATMENT effectiveness, EYE, MEDICAL records, ENUCLEATION of the eye, RETINOBLASTOMA, PROPORTIONAL hazards models
Abstract

Background: Retinoblastoma (RB) outcomes in Thailand are unfavorable compared to those of developed countries. This study aims to determine whether the clinical outcomes of patients with RB significantly improved after the implementation of new therapeutic approaches and which clinical factors affect survival and globe‐saving outcomes. Methods: The medical records of patients newly diagnosed with RB and treated at Siriraj Hospital between January 2005 and December 2018 were reviewed retrospectively. Clinical data, treatments, and outcomes were collected and analyzed. Results: In 194 eyes (144 patients), leukocoria was the most common presenting feature (76.8%); 129 (66.5%) eyes were staged in group E of the International Classification of Intraocular Retinoblastoma. Of the 149 enucleated eyes, 35 had high‐risk histopathological features, mostly choroidal invasion; 45 eyes (23.2%) could be salvaged. The 5‐year overall survival rate was 90.3%, an improvement compared to the previous study. The 5‐year enucleation‐free survival rates of Groups A and B, C, D and E were 100%, 83.1%, 36.7% and 16.6% respectively. Factors associated with a lower survival rate were interval from symptom onset to diagnosis >3 months (hazard ratio (HR): 5.8: 95% confidence interval (CI): 1.637, 20.579) and buphthalmos (HR: 12.57: 95% CI: 3.936, 40.153). Factors associated with high‐risk features were secondary glaucoma (HR: 11.016: 95% CI: 1.24, 98.10) and pseudohypopyon (HR: 14.110: 95% CI: 2.16, 92.05). Conclusions: Survival rates and globe‐saving rates appear to have improved; however, advanced‐stage presentation remains the major hindrance. Further studies with a larger cohort and longer follow‐up are warranted. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

23. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.

Author

Takpradit, Chayamon, Viprakasit, Vip, Narkbunnam, Nattee, Vathana, Nassawee, Phuakpet, Kamon, Pongtanakul, Bunchoo, Sanpakit, Kleebsabai, and Buaboonnam, Jassada

Subjects
IRON overload, BENZENE derivatives, COMBINATION drug therapy, LIVER blood-vessels, FERRITIN, IRON in the body, DEFEROXAMINE, TREATMENT effectiveness, DESCRIPTIVE statistics, THALASSEMIA, DRUG side effects, DRUG toxicity, PHARMACODYNAMICS, DISEASE complications, EVALUATION
Abstract

Background: Iron overload is a major complication of transfusion‐dependent thalassemia (TDT) and requires iron chelation (IC) therapy. However, a combination therapy may be required for patients responding poorly to monotherapy. Methods: Nine TDT patients previously treated with IC were enrolled; five patients were previously treated with deferasirox (DFX) twice daily. The dose of DFX was 20–40 mg/kg/day, while the dose of deferoxamine (DFO) was 18–40 mg/kg/day for 3–6 days/week. Results: At the 6‐ and 12‐month time points, six and eight patients demonstrated decreased serum ferritin levels, with median reductions of 707 ng/mL (range, 1,653–5,444 ng/mL) and 1,129 ng/mL (range, 1,781–7,725 ng/mL) compared to the baseline, respectively. Eight patients also had a reduced liver iron concentration (LIC), with a median reduction of 3.9 mg/g dry wt (range, 8.3–11.1 mg/g dry wt). Of the five patients treated with DFX twice daily, four responded to combination therapy. All responsive patients could finally stop DFO after the decline in LIC. Moreover, there were no treatment‐related complications. Conclusion: The combination of DFX and DFO proved to be effective and without significant toxicities for TDT patients who had been unresponsive to standard IC therapy. Further studies with a larger cohort size and long‐term follow‐up are warranted to elucidate the efficacy of the combination. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

26. Effect of NUDT15 on incidence of neutropenia in children with acute lymphoblastic leukemia.

Author

Buaboonnam, Jassada, Sripatanatadasakul, Pariwan, Treesucon, Ajjima, Glomglao, Waraporn, Siraprapapat, Preeyanun, Narkbunnam, Nattee, Vathana, Nassawee, Takpradit, Chayamon, Phuakpet, Kamon, Pongtanakul, Bunchoo, Tongsai, Sasima, Sinlapamongkolkul, Phakatip, and Sanpakit, Kleebsabai

Subjects
*LYMPHOBLASTIC leukemia prognosis, *NEUTROPENIA, *LYMPHOBLASTIC leukemia diagnosis, *ANTIMETABOLITES, *CONFIDENCE intervals, *GENETIC polymorphisms, *HYDROLASES, *LYMPHOBLASTIC leukemia, *RISK assessment, *SURVIVAL, *GENETIC testing, *TREATMENT effectiveness, *DISEASE incidence, *RETROSPECTIVE studies, *ODDS ratio, *CHILDREN, *DISEASE risk factors
Abstract

Background: 6‐Mercaptopurine (6‐MP) is considered the backbone of therapy in the maintenance phase of acute lymphoblastic leukemia (ALL). Gene polymorphisms involved in thiopurine degradation are predictors of toxicity in patients treated with 6‐MP. We investigated the effects of nucleoside diphosphate linked moiety X (nudix) type motif 15 (NUDT15) polymorphism NUDT15c.415C>T on neutropenia incidence, dose adjustment for 6‐MP, and survival rates in Thai children with ALL. Methods: Children diagnosed with ALL who received 6‐MP in the maintenance phase of treatment, in 2005–2016, were retrospectively enrolled. Results: The subjects consisted of 102 patients (median age, 5.2 years; 58 boys). On genetic testing 78, 22, and two patients were normal (CC), heterozygous (CT), and homozygous (TT), respectively. The incidence of neutropenia at 3 months was significantly higher in the CT/TT than CC polymorphism groups (OR, 12; 95%CI: 3.781–38.085, P < 0.001). The mean dose of 6‐MP at 3, 6, and 12 months was significantly lower in the CT/TT versus the CC group (P < 0.001). The 5 year overall survival (OS) rate for CC was 80.4%, and for CT/TT, 95.5% (P = 0.34). The 5 year event‐free survival (EFS) for CC and CT/TT was 75.1% and 85.7%, respectively (P = 0.17). After adjusted risk classification, no significant differences were observed for OS or EFS between the CC and CT/TT groups. Conclusion: Patients harboring the CT/TT polymorphism of NUDT15 had a significantly higher incidence of neutropenia during the first 3 months of maintenance, resulting in significantly lower doses of 6‐MP. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

27. Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study.

Author

Buaboonnam, Jassada, Narkbunnam, Nattee, Vathana, Nassawee, Takpradit, Chayamon, Phuakpet, Kamon, Pongtanakul, Bunchoo, Tongsai, Sasima, Atchaneeyasakul, La-Ongsri, and Sanpakit, Kleebsabai

Subjects
*RETINOBLASTOMA, *RADIOTHERAPY
Abstract

Retinoblastoma is the most common intraocular malignancy in children. The aim of this study was to investigate the efficacy and toxicity of combination ifosfamide, carboplatin, etoposide, and vincristine (ICEV) in advanced-stage pediatric retinoblastoma [International Classification of Retinoblastoma (ICRB) group D or E], and in ICRB group C in the second eye in simultaneously treated bilateral retinoblastoma. The medical records of retinoblastoma patients treated with concurrent ICEV regimen and focal therapy were retrospectively reviewed. The ICEV treatment protocol was, as follows: ifosfamide 1800 mg/m2 on Days 1–3; MESNA 600 mg/m2 on Days 1–3; carboplatin 560 mg/m2 on Day 1; etoposide 150 mg/m2 on Days 1–3; and vincristine 1.5 mg/m2 on Day 1. Of 16 retinoblastoma patients, 13 had bilateral disease. Seven first eyes in bilateral disease that were enucleated prior to ICEV therapy were excluded. Twenty-two eyes were finally included (six group C, six group D, and ten group E). Median follow-up was 3.4 years, and the median number of ICEV courses was 7. Fifteen globes could be salvaged, 12 responded to ICEV (six group C, five group D, and one group E), and three unresponsive eyes could be salvaged with external beam radiation therapy (EBRT). Enucleation-free and relapse-free survival was 68.2 and 54.5%, respectively. The results of this study suggest ICEV as an alternative therapeutic approach for globe salvage in pediatric retinoblastoma, especially in ICRB groups C and D with manageable acute toxicity. Further study in larger cohort is needed to confirm the effectiveness of treatment. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

29. Severe Deferiprone-Induced Arthropathy in Young Adolescent Successfully Treated with Intraarticular Triamcinolone Acetonide Injection: A Case Report.

Author

Buaboonnam, Jassada and Charuvanij, Sirirat

Subjects
JOINT diseases, TRIAMCINOLONE acetonide, TREATMENT of arthritis, CHELATION therapy, ARTHROCENTESIS, THALASSEMIA treatment, DRUG side effects, NONSTEROIDAL anti-inflammatory agents, THERAPEUTICS
Abstract

Deferiprone (DFP), an oral chelation therapy, has improved treatment adherence and quality of life of transfusion dependent thalassemia (TDT). DFP-induced arthropathy is usually mild and self-limited; the severe DFP-induced arthropathy is uncommon presentation. Herein, a Thai girl diagnosed as TDT was initially treated with DFP. She subsequently developed severe DFP-induced bilateral knee arthritis despite discontinuing DFP and using non-steroidal anti-inflammatory drugs (NSAIDs). She was treated with arthrocentesis and intraarticular triamcinolone acetonide injection and responded well to the treatment. [ABSTRACT FROM AUTHOR]

Published
2017

31. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.

Author

Sriyapai T, Thongyai K, Phuakpet K, Vathana N, Buaboonnam J, and Sanpakit K

Subjects
Adolescent, Child, Cisplatin adverse effects, Hearing, Humans, Retrospective Studies, Thailand epidemiology, Antineoplastic Agents adverse effects, Hearing Loss chemically induced, Hearing Loss epidemiology, Neoplasms, Ototoxicity epidemiology, Ototoxicity etiology
Abstract

Background: Hearing is essential in child development. Cisplatin which is a common chemotherapy used in many pediatric solid-tumor protocols cause various degrees of ototoxicity. Several risk factors for cisplatininduced ototoxicity have been reported, including race and age. This study aimed to evaluate the incidence of ototoxicity and its long-term outcome in Thai pediatric solid-tumor patients receiving cisplatin and to determine the risk factors associated with hearing impairment., Methods: A retrospective study was conducted in solid-tumor patients < 15 years old from 2007 to 2019 at Siriraj Hospital, Bangkok, Thailand. Hearing was evaluated by an audiogram and/or auditory steady-state response and the impairment was graded according to the Common Terminology Criteria for Adverse Events version 5. Grade 2 and above was considered significant hearing loss., Results: In total, the hearing of 47 patients was evaluated. At the end of treatment, hearing impairment and significant hearing loss were found in 66% and 48.9% of patients, respectively. A high median cumulative cisplatin dose was significantly associated with worse hearing impairment (p = 0.039) and a more progressive grading of ototoxicity (p = 0.005). A risk factor for significant hearing loss was a cumulative dose ≥400 mg/m2 (p = 0.014). All 9 patients who received a cumulative dose > 600 mg/m2 and 5 patients who received aminoglycoside developed significant hearing loss. One patient had progressive hearing impairment at 8 months after the end of treatment and 1 patient developed grade 3 ototoxicity which required a hearing aid after bone marrow transplantation. The latter patient received a total cisplatin dose of 708.2 mg/m < sup > 2 < /sup > and carboplatin 1400 mg/m < sup > 2 < /sup > ., Conclusions: The incidence of hearing impairment in pediatric patients receiving cisplatin is high. Regular hearing evaluation is essential for the early detection of ototoxicity. Long-term follow-up is recommended, especially in patients who have a combination of other risk factors for hearing loss.

Published
2022
Full Text
View/download PDF

32. Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing.

Author

Buaboonnam J, Takpradit C, Viprakasit V, Narkbunnam N, Vathana N, Phuakpet K, Sanpakit K, and Pongtanakul B

Abstract

Background: Patients with transfusion-dependent thalassemia ( TDT ) risk iron overload and require iron chelation therapy. Second-line therapy is warranted for patients demonstrating poor chelation responses., Patients and Methods: We retrospectively studied the serum-ferritin (SF), and liver-iron-concentration (LIC) outcomes of patients with TDT treated with twice-daily dosing of deferasirox (TDD-DFX) > 24 months, after failing to respond to once-daily deferasirox (OD-DFX)., Results: We enrolled 22 OD-DFX nonresponders (14 males and eight females; median age, 9.2 [3-15.5] years). The median blood transfusion was 216 (206-277) ml/kg/year. The median TDD-DFX treatment period was 30 (24-35) months. Before initiating TDD-DFX, the median SF level was 2,486 (1,562-8,183) ng/ml, while the median LIC was 6.6 (3.2-19) mg/g dry wt. There were 18 TDD-DFX responders (81.8%) and 4 TDD-DFX nonresponders. The median SF-level change was -724 (-4,916 to 1,490) ng/mL. The median LIC change was -2.14 (-13.7 to 6.8) mg/g dry wt. The 1-year and 2-year SF levels and LICs were statistically significant (SF, P = 0.006/0.005; and LIC, 0.006/0.005, respectively). There were no treatment interruptions secondary to adverse events. In the follow-up of the TDD-DFX responder group, 11 of the 18 had a reduced dose, whereas the remaining seven continued with the same dose., Conclusions: TDD-DFX appears to be an alternative treatment approach for patients refractory to OD-DFX, with a favorable long-term safety profile. Further studies with larger groups and pharmacogenetic analyses of OD-DFX responders are warranted to determine the efficacy and safety profile of TDD-DFX., Competing Interests: Competing interests: The authors declare no conflict of Interest.

Published
2021
Full Text
View/download PDF

33. Invasive Fungal Diseases in Children with Acute Leukemia and Severe Aplastic Anemia.

Author

Supatharawanich S, Narkbunnam N, Vathana N, Takpradit C, Phuakpet K, Pongtanakul B, Tongsai S, Sinlapamongkolkul P, Ngamskulrungroj P, Phongsamart W, Sanpakit K, and Buaboonnam J

Abstract

Although the outcomes of childhood leukemia and severe aplastic anemia (SAA) have improved, infectious complications are still the major concern. Particularly worrisome are invasive fungal diseases (IFDs), one of the most common causes of infectious-related deaths in patients with prolonged neutropenia. A retrospective study was conducted of IFDs in pediatric patients with newly diagnosed or relapsed acute leukemia, or with SAA, at Siriraj Hospital, Mahidol University, Thailand. There were 241 patients: 150 with acute lymphoblastic leukemia (ALL), 35 with acute myeloid leukemia (AML), 31 with relapsed leukemia, and 25 with SAA. Their median age was 5.4 years (range, 0.3-16.0 years). The overall IFD prevalence was 10.7%, with a breakdown in the ALL, AML, relapsed leukemia, and SAA patients of 8%, 11.4%, 19.3%, and 16%, respectively. Pulmonary IFD caused by invasive aspergillosis was the most common, accounting for 38.5% of all infection sites. Candidemia was present in 34.6% of the IFD patients; Candida tropicalis was the most common organism. The overall case-fatality rate was 38.5%, with the highest rate found in relapsed leukemia (75%). The incidences of IFDs in patients with relapsed leukemia and SAA who received fungal prophylaxis were significantly lower than in those who did not ( P = N/A and 0.04, respectively). IFDs in Thai children with hematological diseases appeared to be prevalent, with a high fatality rate. The usage of antifungal prophylaxes should be considered for patients with SAA to prevent IFDs., Competing Interests: Competing interests: The authors declare no conflict of Interest.

Published
2021
Full Text
View/download PDF

34. An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia.

Author

Tanaka Y, Yeoh AEJ, Moriyama T, Li CK, Kudo K, Arakawa Y, Buaboonnam J, Zhang H, Liu HC, Ariffin H, Chen Z, Kham SKY, Nishii R, Hasegawa D, Fujimura J, Keino D, Kondoh K, Sato A, Ueda T, Yamamoto M, Taneyama Y, Hino M, Takagi M, Ohara A, Ito E, Koh K, Hori H, Manabe A, Yang JJ, and Kato M

Subjects
Alleles, Child, Humans, Pyrophosphatases genetics, Retrospective Studies, Mercaptopurine adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
Published
2021
Full Text
View/download PDF

35. Global Retinoblastoma Presentation and Analysis by National Income Level.

Author

Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, Adio A, Afshar AR, Aggarwal P, Aghaji AE, Ahmad A, Akib MNR, Al Harby L, Al Ani MH, Alakbarova A, Portabella SA, Al-Badri SAF, Alcasabas APA, Al-Dahmash SA, Alejos A, Alemany-Rubio E, Alfa Bio AI, Alfonso Carreras Y, Al-Haddad C, Al-Hussaini HHY, Ali AM, Alia DB, Al-Jadiry MF, Al-Jumaily U, Alkatan HM, All-Eriksson C, Al-Mafrachi AARM, Almeida AA, Alsawidi KM, Al-Shaheen AASM, Al-Shammary EH, Amiruddin PO, Antonino R, Astbury NJ, Atalay HT, Atchaneeyasakul LO, Atsiaya R, Attaseth T, Aung TH, Ayala S, Baizakova B, Balaguer J, Balayeva R, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Benavides R, Benmiloud S, Bennani Guebessi N, Berete RC, Berry JL, Bhaduri A, Bhat S, Biddulph SJ, Biewald EM, Bobrova N, Boehme M, Boldt HC, Bonanomi MTBC, Bornfeld N, Bouda GC, Bouguila H, Boumedane A, Brennan RC, Brichard BG, Buaboonnam J, Calderón-Sotelo P, Calle Jara DA, Camuglia JE, Cano MR, Capra M, Cassoux N, Castela G, Castillo L, Català-Mora J, Chantada GL, Chaudhry S, Chaugule SS, Chauhan A, Chawla B, Chernodrinska VS, Chiwanga FS, Chuluunbat T, Cieslik K, Cockcroft RL, Comsa C, Correa ZM, Correa Llano MG, Corson TW, Cowan-Lyn KE, Csóka M, Cui X, Da Gama IV, Dangboon W, Das A, Das S, Davanzo JM, Davidson A, De Potter P, Delgado KQ, Demirci H, Desjardins L, Diaz Coronado RY, Dimaras H, Dodgshun AJ, Donaldson C, Donato Macedo CR, Dragomir MD, Du Y, Du Bruyn M, Edison KS, Eka Sutyawan IW, El Kettani A, Elbahi AM, Elder JE, Elgalaly D, Elhaddad AM, Elhassan MMA, Elzembely MM, Essuman VA, Evina TGA, Fadoo Z, Fandiño AC, Faranoush M, Fasina O, Fernández DDPG, Fernández-Teijeiro A, Foster A, Frenkel S, Fu LD, Fuentes-Alabi SL, Gallie BL, Gandiwa M, Garcia JL, García Aldana D, Gassant PY, Geel JA, Ghassemi F, Girón AV, Gizachew Z, Goenz MA, Gold AS, Goldberg-Lavid M, Gole GA, Gomel N, Gonzalez E, Gonzalez Perez G, González-Rodríguez L, Garcia Pacheco HN, Graells J, Green L, Gregersen PA, Grigorovski NDAK, Guedenon KM, Gunasekera DS, Gündüz AK, Gupta H, Gupta S, Hadjistilianou T, Hamel P, Hamid SA, Hamzah N, Hansen ED, Harbour JW, Hartnett ME, Hasanreisoglu M, Hassan S, Hassan S, Hederova S, Hernandez J, Hernandez LMC, Hessissen L, Hordofa DF, Huang LC, Hubbard GB, Hummlen M, Husakova K, Hussein Al-Janabi AN, Ida R, Ilic VR, Jairaj V, Jeeva I, Jenkinson H, Ji X, Jo DH, Johnson KP, Johnson WJ, Jones MM, Kabesha TBA, Kabore RL, Kaliki S, Kalinaki A, Kantar M, Kao LY, Kardava T, Kebudi R, Kepak T, Keren-Froim N, Khan ZJ, Khaqan HA, Khauv P, Kheir WJ, Khetan V, Khodabande A, Khotenashvili Z, Kim JW, Kim JH, Kiratli H, Kivelä TT, Klett A, Komba Palet JEK, Krivaitiene D, Kruger M, Kulvichit K, Kuntorini MW, Kyara A, Lachmann ES, Lam CPS, Lam GC, Larson SA, Latinovic S, Laurenti KD, Le BHA, Lecuona K, Leverant AA, Li C, Limbu B, Long QB, López JP, Lukamba RM, Lumbroso L, Luna-Fineman S, Lutfi D, Lysytsia L, Magrath GN, Mahajan A, Majeed AR, Maka E, Makan M, Makimbetov EK, Manda C, Martín Begue N, Mason L, Mason JO 3rd, Matende IO, Materin M, Mattosinho CCDS, Matua M, Mayet I, Mbumba FB, McKenzie JD, Medina-Sanson A, Mehrvar A, Mengesha AA, Menon V, Mercado GJVD, Mets MB, Midena E, Mishra DKC, Mndeme FG, Mohamedani AA, Mohammad MT, Moll AC, Montero MM, Morales RA, Moreira C, Mruthyunjaya P, Msina MS, Msukwa G, Mudaliar SS, Muma KI, Munier FL, Murgoi G, Murray TG, Musa KO, Mushtaq A, Mustak H, Muyen OM, Naidu G, Nair AG, Naumenko L, Ndoye Roth PA, Nency YM, Neroev V, Ngo H, Nieves RM, Nikitovic M, Nkanga ED, Nkumbe H, Nuruddin M, Nyaywa M, Obono-Obiang G, Oguego NC, Olechowski A, Oliver SCN, Osei-Bonsu P, Ossandon D, Paez-Escamilla MA, Pagarra H, Painter SL, Paintsil V, Paiva L, Pal BP, Palanivelu MS, Papyan R, Parrozzani R, Parulekar M, Pascual Morales CR, Paton KE, Pawinska-Wasikowska K, Pe'er J, Peña A, Peric S, Pham CTM, Philbert R, Plager DA, Pochop P, Polania RA, Polyakov VG, Pompe MT, Pons JJ, Prat D, Prom V, Purwanto I, Qadir AO, Qayyum S, Qian J, Rahman A, Rahman S, Rahmat J, Rajkarnikar P, Ramanjulu R, Ramasubramanian A, Ramirez-Ortiz MA, Raobela L, Rashid R, Reddy MA, Reich E, Renner LA, Reynders D, Ribadu D, Riheia MM, Ritter-Sovinz P, Rojanaporn D, Romero L, Roy SR, Saab RH, Saakyan S, Sabhan AH, Sagoo MS, Said AMA, Saiju R, Salas B, San Román Pacheco S, Sánchez GL, Sayalith P, Scanlan TA, Schefler AC, Schoeman J, Sedaghat A, Seregard S, Seth R, Shah AS, Shakoor SA, Sharma MK, Sherief ST, Shetye NG, Shields CL, Siddiqui SN, Sidi Cheikh S, Silva S, Singh AD, Singh N, Singh U, Singha P, Sitorus RS, Skalet AH, Soebagjo HD, Sorochynska T, Ssali G, Stacey AW, Staffieri SE, Stahl ED, Stathopoulos C, Stirn Kranjc B, Stones DK, Strahlendorf C, Suarez MEC, Sultana S, Sun X, Sundy M, Superstein R, Supriyadi E, Surukrattanaskul S, Suzuki S, Svojgr K, Sylla F, Tamamyan G, Tan D, Tandili A, Tarrillo Leiva FF, Tashvighi M, Tateshi B, Tehuteru ES, Teixeira LF, Teh KH, Theophile T, Toledano H, Trang DL, Traoré F, Trichaiyaporn S, Tuncer S, Tyau-Tyau H, Umar AB, Unal E, Uner OE, Urbak SF, Ushakova TL, Usmanov RH, Valeina S, van Hoefen Wijsard M, Varadisai A, Vasquez L, Vaughan LO, Veleva-Krasteva NV, Verma N, Victor AA, Viksnins M, Villacís Chafla EG, Vishnevskia-Dai V, Vora T, Wachtel AE, Wackernagel W, Waddell K, Wade PD, Wali AH, Wang YZ, Weiss A, Wilson MW, Wime ADC, Wiwatwongwana A, Wiwatwongwana D, Wolley Dod C, Wongwai P, Xiang D, Xiao Y, Yam JC, Yang H, Yanga JM, Yaqub MA, Yarovaya VA, Yarovoy AA, Ye H, Yousef YA, Yuliawati P, Zapata López AM, Zein E, Zhang C, Zhang Y, Zhao J, Zheng X, Zhilyaeva K, Zia N, Ziko OAO, Zondervan M, and Bowman R

Subjects
Child, Preschool, Female, Humans, Infant, Male, Retinoblastoma economics, Retinoblastoma epidemiology
Abstract

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale., Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis., Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017., Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis., Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68])., Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs.

Published
2020
Full Text
View/download PDF

36. Bisphosphonate Therapy for Refractory Langerhans Cell Histiocytosis: A Case Report.

Author

Takpradit C, Vathana N, Narkbunnam N, Sanpakit K, and Buaboonnam J

Subjects
Female, Humans, Infant, Pamidronate, Thailand, Antineoplastic Agents therapeutic use, Diphosphonates therapeutic use, Histiocytosis, Langerhans-Cell drug therapy, Neoplasm Recurrence, Local drug therapy
Abstract

Although patients diagnosed as Langerhans cell histiocytosis (LCH) with bone lesion initially respond well to treatment, some may experience relapse or refractory disease. Pamidronate, a potent N-bisphosphonate, has been used in several primary bone diseases, benign bone tumors, and metastatic bone cancers. The mechanism includes an inhibitory effect on osteoclast activity by decreasing development and recruitment of osteoclast progenitors and promoting osteoclast apoptosis. Herein, we introduce a seven-month-old Thai girl who was diagnosed as multiple-relapse LCH with refractory bone lesions and was treated with standard and salvage steroid-based therapies. After receiving two courses of intravenous pamidronate, she had marked clinical and radiographical improvement without any adverse events. She has been in remission for two years after receiving six courses of therapy. This report supports the efficacy ofpamidronate in LCH-related bone lesions, but further studies in large cohort are warranted.

Published
2015

37. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Author

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, and Inaba H

Subjects
Adolescent, Alleles, Animals, Antineoplastic Agents chemistry, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Child, Drug Resistance, Neoplasm genetics, Female, Humans, Indoles chemistry, Male, Mice, Models, Molecular, Molecular Conformation, Niacinamide chemistry, Niacinamide therapeutic use, Phenylurea Compounds chemistry, Protein Binding, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors therapeutic use, Pyrroles chemistry, Sorafenib, Sunitinib, Treatment Outcome, fms-Like Tyrosine Kinase 3 chemistry, Indoles therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Mutation, Niacinamide analogs & derivatives, Phenylurea Compounds therapeutic use, Protein Interaction Domains and Motifs genetics, Pyrroles therapeutic use, fms-Like Tyrosine Kinase 3 genetics
Abstract

Purpose: To evaluate the clinical activity of sequential therapy with sorafenib and sunitinib in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive acute myelogenous leukemia (AML) and monitor the emergence of secondary FLT3 tyrosine kinase domain (TKD) mutations during treatment., Experimental Design: Six children with relapsed/refractory AML were treated with sorafenib in combination with clofarabine and cytarabine, followed by single-agent sorafenib if not a candidate for transplantation. Sunitinib was initiated after sorafenib relapse. Bone marrow samples were obtained for assessment of FLT3 TKD mutations by deep amplicon sequencing. The phase of secondary mutations with ITD alleles was assessed by cloning and sequencing of FLT3 exons 14 through 20. Identified mutations were modeled in Ba/F3 cells, and the effect of kinase inhibitors on FLT3 signaling and cell viability was assessed., Results: Four patients achieved complete remission, but 3 receiving maintenance therapy with sorafenib relapsed after 14 to 37 weeks. Sunitinib reduced circulating blasts in two patients and marrow blasts in one. Two patients did not respond to sorafenib combination therapy or sunitinib. FLT3 mutations at residues D835 and F691 were observed in sorafenib resistance samples on both ITD-positive and -negative alleles. Deep sequencing revealed low-level mutations and their evolution during sorafenib treatment. Sunitinib suppressed leukemic clones with D835H and F691L mutations, but not D835Y. Cells expressing sorafenib-resistant FLT3 mutations were sensitive to sunitinib in vitro., Conclusions: Sunitinib has activity in patients that are resistant to sorafenib and harbor secondary FLT3 TKD mutations. The use of sensitive methods to monitor FLT3 mutations during therapy may allow individualized treatment with the currently available kinase inhibitors., (©2013 AACR.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results